JEMPERLI receives recommendation from Canada’s Drug Agency for the treatment of mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer
- Jemperli received a reimburse with conditions recommendation from CDA-AMC marking an important milestone in advancing access to endometrial cancer treatments and securing public reimbursement
- Provincial and territorial governments will make the final decision on public reimbursement
MISSISSAUGA, ON – Jemperli (dostarlimab for injection) has received a reimburse with conditions recommendation from Canada’s Drug Agency (CDA-AMC), formerly the Canadian Agency for Drugs and Technology in Health (CADTH), a Canadian Health Technology Assessment (HTA) body.
CDA-AMC has recommended that Jemperli in combination with carboplatin and paclitaxel be reimbursed with conditions for the treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer who are candidates for systematic therapy. Jemperli was granted Health Canada approval for this indication in November 2023.
"GSK is dedicated to delivering a meaningful solution that effectively addresses the unmet needs of patients in Canada living with endometrial cancer,” says Marni Freeman, Country Medical Director, GSK Canada. "We take great pride and commend CDA-AMC for their recommendation on Jemperli. We look forward to working with the pan-Canadian Pharmaceutical Alliance (pCPA), as well as public and private payers, to actively support reimbursement efforts and ensure widespread and timely access to this critical treatment option.”
An estimated 20-29% of all endometrial cancers are dMMR/MSI-H and patients face significant unmet need experiencing poor long-term outcomes with the current standard of care. [i] Jemperli is the only immuno-oncology treatment option approved for this patient population in combination with chemotherapy in Canada.
“Both timely diagnosis and access to effective treatments are paramount in extending the survival of individuals diagnosed with endometrial cancer,” says Jackie Manthorne, President, and CEO of the Canadian Cancer Survivor Network (CCSN). “We applaud CDA-AMC for their positive recommendation for Jemperli, a significant milestone for Canadians managing the effects of endometrial cancer. I encourage the pCPA and the drug programs to work toward timely reimbursement for Jemperli, as patients cannot wait.”
About endometrial cancer
Endometrial cancer is one of the most common gynaecologic cancers in developed countries,[ii] and there are about 8,100 new cases of endometrial cancer diagnosed every year in Canada.[iii] Approximately 15-20% of patients with endometrial cancer will be diagnosed with advanced disease at the time of diagnosis.[iv][v] An estimated 20-29% of all endometrial cancers are dMMR/MSI-H.[vi] Chemotherapy has been the current standard of care for the majority of patients with primary advanced or recurrent endometrial cancer, and many patients eventually experience disease progression.[vii]
About Jemperli (dostarlimab for injection)
Jemperli is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2. [viii]
In Canada, Jemperli (dostarlimab for injection) is indicated in combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer who are candidates for systemic therapy, and as monotherapy for the treatment of adult patients with dMMR or MSI-H recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum containing regimen.
Please consult the Product Monograph at www.gsk.ca for complete safety information. The Product Monograph is also available by calling 1-800-387-7374.
GSK in gynaecologic oncology
GSK is committed to maximizing patient survival through transformational medicines with a current effort on breakthroughs in oncology, including gynaecologic cancers, some of the most common cancers affecting women. We are focused on developing new medicines across a range of different modalities both as monotherapy and in combination for a variety of cancers, including ovarian and endometrial. We have a unique research and development approach, utilizing synthetic lethality and immuno-oncology to target specific proteins and biomarkers in ovarian cancer and endometrial cancer, enabling us to develop targeted treatments.
About GSK
GSK is a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. Find out more at gsk.ca.
References
[i] Cerner Enviza CancerMPact® [Treatment Architecture]. Available from www.cancermpact.com. Accessed February 2024.
[ii] Faizan U, Muppidi V. Uterine Cancer. [Updated 2022 Sep 5]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available at: https://www.ncbi.nlm.nih.gov/books/NBK562313/.
[iii] Lee, S. (n.d.). Canadian cancer statistics. Canadian Cancer Society. https://cancer.ca/en/research/cancer-statistics/canadian-cancer-statistics.
[iv] Cerner Enviza CancerMPact® Patient Metrics 2022. CMP:CancerMPact® [Patient Metrics], Cerner Enviza. Available from www.cancermpact.com. Accessed February 2024.
[v] CancerMPact® [Treatment Architecture], Cerner Enviza. Available from www.cancermpact.com. Accessed February 2024.
[vi] Cerner Enviza CancerMPact® [Treatment Architecture]. Available from www.cancermpact.com. Accessed February 2024.
[vii] Halla K. Emerging Treatment Options for Advanced or Recurrent Endometrial Cancer. J Adv Pract Oncol. 2022 Jan;13(1):45-59. doi: 10.6004/jadpro.2022.13.1.4. Epub 2022 Feb 1. PMID: 35173988; PMCID: PMC8805805.
[viii] Laken H, Kehry M, Mcneeley P, et al. Identification and characterization of TSR-042, a novel anti-human PD-1 therapeutic antibody. European Journal of Cancer. 2016;69,S102. doi:10.1016/s0959-8049(16)32902-1.
